NZ596820A - Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid - Google Patents
Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acidInfo
- Publication number
- NZ596820A NZ596820A NZ596820A NZ59682010A NZ596820A NZ 596820 A NZ596820 A NZ 596820A NZ 596820 A NZ596820 A NZ 596820A NZ 59682010 A NZ59682010 A NZ 59682010A NZ 596820 A NZ596820 A NZ 596820A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- benzazepin
- tetrazol
- tetrahydro
- trifluoromethyl
- Prior art date
Links
- IHIUGIVXARLYHP-UXNJHFGPSA-N Evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2CC1CCC(C(O)=O)CC1 IHIUGIVXARLYHP-UXNJHFGPSA-N 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22170809P | 2009-06-30 | 2009-06-30 | |
| PCT/US2010/040125 WO2011002696A1 (en) | 2009-06-30 | 2010-06-28 | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596820A true NZ596820A (en) | 2013-07-26 |
Family
ID=42352717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596820A NZ596820A (en) | 2009-06-30 | 2010-06-28 | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
Country Status (37)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005267436A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
| ES2683350T3 (es) * | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| WO2014012401A1 (zh) * | 2012-07-16 | 2014-01-23 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
| WO2014119947A1 (en) | 2013-01-31 | 2014-08-07 | Chong Kun Dang Pharmaceutical Corp. | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors |
| CN105017085B (zh) * | 2014-04-28 | 2018-06-29 | 中国科学院上海药物研究所 | 一类kcnq钾通道激动剂、其制备方法和用途 |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| CN108456213B (zh) * | 2017-02-22 | 2021-01-15 | 浙江九洲药业股份有限公司 | 一种3-氟-4-羟基环己烷羧酸酯的制备方法 |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4948639B1 (https=) | 1970-12-15 | 1974-12-23 | ||
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| ATE316957T1 (de) | 2001-04-30 | 2006-02-15 | Pfizer Prod Inc | Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate |
| BR0306208A (pt) | 2002-08-30 | 2004-10-13 | Japan Tobacco Inc | Compostos de dibenzilamina e seu uso farmacêutico |
| AU2003277285B2 (en) * | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| JP2006523218A (ja) | 2003-03-04 | 2006-10-12 | 高砂香料工業株式会社 | 光学活性アミン類の製造方法 |
| US20040204450A1 (en) | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| WO2005037796A1 (en) | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| WO2005097805A1 (en) | 2004-03-26 | 2005-10-20 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| CN1972927A (zh) * | 2004-06-24 | 2007-05-30 | 伊莱利利公司 | 用于治疗血脂障碍的化合物和方法 |
| AU2005267436A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| AR077208A1 (es) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
-
2010
- 2010-06-23 AR ARP100102219A patent/AR077208A1/es unknown
- 2010-06-23 TW TW099120507A patent/TWI450896B/zh not_active IP Right Cessation
- 2010-06-24 JO JO2010211A patent/JO2867B1/en active
- 2010-06-28 RS RS20130453A patent/RS52988B/sr unknown
- 2010-06-28 BR BRPI1011931A patent/BRPI1011931A2/pt not_active IP Right Cessation
- 2010-06-28 JP JP2012517814A patent/JP5689875B2/ja not_active Expired - Fee Related
- 2010-06-28 HR HRP20130950AT patent/HRP20130950T1/hr unknown
- 2010-06-28 KR KR1020117031449A patent/KR101404893B1/ko not_active Expired - Fee Related
- 2010-06-28 PT PT107285587T patent/PT2448933E/pt unknown
- 2010-06-28 CA CA2764425A patent/CA2764425C/en not_active Expired - Fee Related
- 2010-06-28 WO PCT/US2010/040125 patent/WO2011002696A1/en not_active Ceased
- 2010-06-28 MX MX2011014024A patent/MX2011014024A/es active IP Right Grant
- 2010-06-28 UA UAA201115555A patent/UA109409C2/ru unknown
- 2010-06-28 MY MYPI2011006319A patent/MY157121A/en unknown
- 2010-06-28 PL PL10728558T patent/PL2448933T3/pl unknown
- 2010-06-28 SG SG2011097128A patent/SG177413A1/en unknown
- 2010-06-28 US US12/824,355 patent/US8329688B2/en not_active Expired - Fee Related
- 2010-06-28 DK DK10728558.7T patent/DK2448933T3/da active
- 2010-06-28 ME MEP-2013-114A patent/ME01606B/me unknown
- 2010-06-28 NZ NZ596820A patent/NZ596820A/xx not_active IP Right Cessation
- 2010-06-28 SI SI201030386T patent/SI2448933T1/sl unknown
- 2010-06-28 PE PE2011002156A patent/PE20120538A1/es not_active Application Discontinuation
- 2010-06-28 MA MA34490A patent/MA33385B1/fr unknown
- 2010-06-28 EP EP10728558.7A patent/EP2448933B1/en active Active
- 2010-06-28 US US13/318,874 patent/US8299060B2/en not_active Expired - Fee Related
- 2010-06-28 AU AU2010266537A patent/AU2010266537B2/en not_active Ceased
- 2010-06-28 EA EA201270099A patent/EA020600B1/ru not_active IP Right Cessation
- 2010-06-28 ES ES10728558T patent/ES2435293T3/es active Active
- 2010-06-28 CN CN201080029957.9A patent/CN102639528B/zh not_active Expired - Fee Related
-
2011
- 2011-11-25 ZA ZA2011/08707A patent/ZA201108707B/en unknown
- 2011-11-28 IL IL216655A patent/IL216655A/en not_active IP Right Cessation
- 2011-12-12 CR CR20110669A patent/CR20110669A/es not_active Application Discontinuation
- 2011-12-13 TN TNP2011000638A patent/TN2011000638A1/en unknown
- 2011-12-13 GT GT201100321A patent/GT201100321A/es unknown
- 2011-12-22 CL CL2011003263A patent/CL2011003263A1/es unknown
- 2011-12-22 CO CO11177215A patent/CO6480934A2/es active IP Right Grant
- 2011-12-23 EC EC2011011551A patent/ECSP11011551A/es unknown
- 2011-12-26 DO DO2011000405A patent/DOP2011000405A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| WO2012007869A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| WO2009016460A3 (en) | Pyrazole compounds and their use as raf inhibitors | |
| TW200745070A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and their use | |
| TW200745069A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use | |
| WO2006069155A3 (en) | Inhibitors of protein arginine methyl transferases | |
| TW200833663A (en) | Therapeutic agents | |
| NZ602321A (en) | Compound and use for reducing uric acid comprising 2-(3-(2,6-Dimethylbenzyloxy)-4-methylphenyl)acetic acid | |
| JP2012512863A5 (https=) | ||
| WO2007099553A3 (en) | 1,3-dioxane carboxylic acids | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
| GB2454615A (en) | Antidiabetic azabicyclo (3.1.0) hexan compounds | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| EA201101210A1 (ru) | 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh для лечения легочной функции | |
| PH12012501974A1 (en) | Novel hypoglycemic compounds | |
| WO2006051314A3 (en) | Guanidine derivatives as inhibitors of ddah | |
| WO2009053999A3 (en) | Sulfoximine derivatives as factor xa inhibitors | |
| WO2009056617A3 (en) | 4,4-disubstituted piperdines as renin inhibitors | |
| AR083322A1 (es) | Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo | |
| MX2009005250A (es) | Compuestos 2-alquil-indazol para el tratamiento de ciertas enfermedades relacionadas con el sistema nervioso central (cns). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUN 2017 BY THOMSON REUTERS Effective date: 20140320 |
|
| LAPS | Patent lapsed |